Zhejiang Jianfeng Pharmaceutical, a unit of cement maker Zhejiang Jianfeng Group (SHA:600668), obtained a drug registration certificate for diquafosol sodium eye drops from the Chinese drug administration, according to a Shanghai Stock Exchange filing on Thursday.
The certificate for the dry eye treatment is valid until Nov. 30, 2029, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.